Professor Daniela Zisterer
Professor In, Biochemistry
Biography
Daniela Zisterer has been a Principal Investigator and academic member of staff in the School of Biochemistry and Immunology, Trinity College Dublin, since 2000. She was made a Fellow of Trinity College and promoted to Associate Professor in 2007. Her main research programme seeks to understand the molecular mechanisms underlying apoptotic cell death and how deregulated apoptosis leads to cancer with a view to developing novel therapies which target components of this deregulated pathway. Furthermore, she is interested in determining how tumour resistance to chemotherapy relates to cell survival through autophagic mechanisms. The work is multidisciplinary and she collaborates with medicinal chemists, pharmacologists, clinicians and industry partners both nationally and internationally. She is a joint inventor on two patents. Her programme of research is defining new predictive markers, therapeutic targets and new therapies suitable for commercial development and clinical trial interventions that could improve cancer patient outcome. Prof. Zisterer has published over one hundred research articles in highly ranked international journals including British Journal of Cancer, Journal of Biological Chemistry and Cancer Research. To date, she has supervised or co-supervised 18 PhD students to completion. She has secured over 3.9 million in research funding from a variety of sources including the European Union, Science Foundation Ireland and the Health Research Board. She is currently project coordinator of an international, inter-sectoral Horizons 2020 Marie Skłodowska-Curie innovative PhD training network entitled Training in Cancer mechanisms and Therapeutics (TRACT), which has secured funding of 2.9 million. Prof Zisterer actively contributes to college life. She is currently Head of Discipline of Biochemistry and has previously served as Director of Undergraduate Teaching & Learning and Director of Research for the School of Biochemistry & Immunology. She is committed to undergraduate teaching and has been Director of the undergraduate degree programme in Biochemistry since 2000.
Publications and Further Research Outputs
Peer-Reviewed Publications
McKenna, S.M. and Florea, B.I. and Zisterer, D.M. and van Kasteren, S.I. and McGouran, J.F., Probing the metalloproteome: an 8-mercaptoquinoline motif enriches minichromosome maintenance complex components as significant metalloprotein targets in live cells, RSC Chemical Biology, 5, (8), 2024, p776-786
Gao, T. and Magnano, S. and Rynne, A. and O'Kane, L. and Barroeta, P.H. and Zisterer, D.M., Targeting inhibitor of apoptosis proteins (IAPs) enhances susceptibility of oral squamous carcinoma cells to cisplatin, Experimental Cell Research, 437, (1), 2024
McLoughlin E.C., Twamley B., O'Brien J.E., Hannon Barroeta P., Zisterer D.M., Meegan M.J., O'Boyle N.M., Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers, Bioorganic Chemistry, 141, 2023
Wang S., Malebari A.M., Greene T.F., Kandwal S., Fayne D., Nathwani S.M., Zisterer D.M., Twamley B., O'Boyle N.M., Meegan M.J., Antiproliferative and Tubulin-Destabilising Effects of 3-(Prop-1-en-2-yl)azetidin-2-Ones and Related Compounds in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 16, (7), 2023, p1000-
Hannon Barroeta, P. and Oâ Sullivan, M.J. and Zisterer, D.M., The role of the Nrf2/GSH antioxidant system in cisplatin resistance in malignant rhabdoid tumours, Journal of Cancer Research and Clinical Oncology, 149, (11), 2023, p8379-8391
Byrne A.J., Bright S.A., McKeown J.P., Bergin A., Twamley B., McElligott A.M., Noorani S., Kandwal S., Fayne D., O'Boyle N.M., Williams D.C., Meegan M.J., Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL), Molecules, 28, (24), 2023
Coyle, R. and O'Sullivan, M.J. and Zisterer, D.M., Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatin, Cancer Treatment and Research Communications, 32, (100579), 2022
McCabe, N.H. and Stevenson, L. and Scanlon, E. and Douglas, R. and Kennedy, S. and Keminer, O. and WindshÃŒgel, B. and Zisterer, D. and Kennedy, R.D. and Blayney, J.K. and Turkington, R.C., Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches, Cancers, 14, (15), 2022
Rebecca Amet, Viola Previtali, Helene B. Mihigo, Emily Sheridan, Sarah Brophy , Nadhim Kamil Hante, Maria Jose Santos-Martinez, Patrick J. Hayden, Paul V. Browne, Isabel Rozas, Anthony M. McElligott , Daniela M. Zisterer , A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma , Life Sciences, 290, 2022
Campiani, G. and Khan, T. and Ulivieri, C. and Staiano, L. and Papulino, C. and Magnano, S. and Nathwani, S. and Ramunno, A. and Lucena-Agell, D. and Relitti, N. and Federico, S. and Pozzetti, L. and Carullo, G. and Casagni, A. and Brogi, S. and Vanni, F. and Galatello, P. and Ghanim, M. and McCabe, N. and Lamponi, S. and Valoti, M. and Ibrahim, O. and O'Sullivan, J. and Turkington, R. and Kelly, V.P. and VanWemmel, R. and DÃaz, J.F. and Gemma, S. and Zisterer, D. and Altucci, L. and De Matteis, A. and Butini, S. and Benedetti, R., Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy, European Journal of Medicinal Chemistry, 235, (114274), 2022
Hannon Barroeta, P. and Magnano, S. and O'Sullivan, M.J. and Zisterer, D.M., Evaluation of targeting autophagy for the treatment of malignant rhabdoid tumours, Cancer Treatment and Research Communications, 32, (100584), 2022
Malebari AM, Duffy Morales G, Twamley B, Fayne D, Khan MF, McLoughlin EC, O'Boyle NM, Zisterer DM, Meegan MJ., Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones., Pharmaceuticals (Basel, Switzerland), 15, (9), 2022, p1044
Vanni, F. and Lopresti, L. and Zurli, V. and Kabanova, A. and Cattaneo, F. and Sicuranza, A. and Gozzetti, A. and Gemma, S. and Zisterer, D.M. and Bocchia, M. and Campiani, G. and Baldari, C.T. and Butini, S. and Ulivieri, C., A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in EΌ-TCL1 mice through the JNK/STAT4/p66Shc axis, Pharmacological Research, 174, (105965), 2021
Gloria Ana, Patrick M. Kelly, Azizah M. Malebari, Sara Noorani, Seema M. Nathwani, Brendan Twamley, Darren Fayne, Niamh M. O'Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer and Mary J. Meegan, Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-Triazoles and 1-(Diarylmethyl)-1H-Imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer, Pharmaceuticals, 14, (2), 2021, p169-
Magnano S, Hannon Barroeta P, Duffy R, O'Sullivan J, Zisterer DM., Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species., Toxicology and applied pharmacology, 427, 2021, p115646
Malebari A.M., Wang S., Greene T.F., O'Boyle N.M., Fayne D., Khan M.F., Nathwani S.M., Twamley B., McCabe T., Zisterer D.M., Meegan M.J., Synthesis and antiproliferative evaluation of 3-chloroazetidin-2-ones with antimitotic activity: Heterocyclic bridged analogues of combretastatin A-4, Pharmaceuticals, 14, (11), 2021, part. 1119-
Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., Beta-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020
Khan, T. and Relitti, N. and Brindisi, M. and Magnano, S. and Zisterer, D. and Gemma, S. and Butini, S. and Campiani, G., Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas, Medicinal Research Reviews, 40, (3), 2020, p1002-1060
Relitti, N. and Saraswati, A.P. and Federico, S. and Khan, T. and Brindisi, M. and Zisterer, D. and Brogi, S. and Gemma, S. and Butini, S. and Campiani, G., Telomerase-based cancer therapeutics: A review on their clinical trials, Current Topics in Medicinal Chemistry, 20, (6), 2020, p433-457
Malebari, A.M. and Fayne, D. and Nathwani, S.M. and O'Connell, F. and Noorani, S. and Twamley, B. and O'Boyle, N.M. and O'Sullivan, J. and Zisterer, D.M. and Meegan, M.J., β-Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, (112050), 2020
A. Prasanth Saraswati, Nicola Relitti, Margherita Brindisi, Jeremy D. Osko, Giulia Chemi, Stefano Federico, Alessandro Grillo, Simone Brogi, Niamh H. McCabe, Richard C. Turkington, Ola Ibrahim, Jeffrey O'Sullivan, Stefania Lamponi, Magda Ghanim, Vincent P. Kelly, Daniela Zisterer, Rebecca Amet, Patricia Hannon, Francesca Vanni, Cristina Ulivieri, Daniel Herp, Federica Sarno, Antonella Di Costanzo, Fulvio Saccoccia, Giovina Ruberti, Manfred Jung, Lucia Altucci, Sandra Gemma, Stefania Butini, David W. Christianson, and Giuseppe Campiani, Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, 2 Synthesis, Structural Analysis, and Biological Evaluation , ACS Medicinal Chemistry Letters, 2020
Azizah M. Malebari, Darren Fayne, Seema M. Nathwani, Fiona O'Connell, Sara Noorani, Brendan Twamley, Niamh M. O'Boyle, Jacintha O'Sullivan, Daniela M. Zisterer, Mary J. Meegan, Beta-lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells, European Journal of Medicinal Chemistry, 189, 2020, p112050-
Miriam Carr, Andrew J.S. Knox, Daniel K. Nevin, Niamh O'Boyle, Shu Wang, Billy Egan, Thomas McCabe, Brendan Twamley, Daniela M. Zisterer, David G. Lloyd, Mary J. Meegan, Optimisation of Estrogen Receptor Subtype-Selectivity of a 4-Aryl-4H-Chromene Scaffold Previously Identified by Virtual Screening, Bioorganic & Medicinal Chemistry, 28, (5), 2020, p115261-
Viola Previtali , Helene B Mihigo , Rebecca Amet, Anthony M McElligott , Daniela M Zisterer , Isabel Rozas , Exploring the Anti-Cancer Mechanism of Novel 3,4'-Substituted Diaryl Guanidinium Derivatives, Pharmaceuticals (Basel), 13, (12), 2020, p485
O'Boyle, N.M. and Ana, G. and Kelly, P.M. and Nathwani, S.M. and Noorani, S. and Fayne, D. and Bright, S.A. and Twamley, B. and Zisterer, D.M. and Meegan, M.J., Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates, Organic and Biomolecular Chemistry, 17, (25), 2019, p6184-6200
Coyle, R. and Slattery, K. and Ennis, L. and O'Sullivan, M.J. and Zisterer, D.M. , The XIAP inhibitor embelin sensitises malignant rhabdoid tumour cells to TRAIL treatment via enhanced activation of the extrinsic apoptotic pathway, International Journal of Oncology, 55, (1), 2019, p191-202
Wang, S., Malebari, A.M., Greene, T.F., O'Boyle, N.M., Fayne, D., Nathwani, S.M., Twamley, B., McCabe, T., Keely, N.O., Zisterer, D.M. and Meegan, M.J., 3-Vinylazetidin-2-Ones: Synthesis, antiproliferative and tubulin destabilizing activity in MCF-7 and MDA-MB-231 Breast Cancer Cells, Pharmaceuticals, 12, (2), 2019
Saraswati AP, Relitti N, Brindisi M, Gemma S, Zisterer D, Butini S & Campiani G, Raising the bar in anticancer therapy:recent advances in, and perspectives on, telomerase inhibitors, Drug Discovery Today, 2019
Margherita Brindisi, Cristina Ulivieri, Gloria Alfano, Sandra Gemma,Francisco de Asís Balaguer, Tuhina Khan, Alessandro Grillo, Giulia Chemi, Grégory Menchon, Andrea E. Prota, Natacha Olieric, Daniel Lucena-Agell, Isabel Barasoain, J. Fernando Diaz, Angela Nebbioso, Maria Rosaria Conte, Ludovica Lopresti, Stefania Magnano, Rebecca Amet, Paula Kinsella, Daniela M. Zisterer, Ola Ibrahim, Jeff O'Sullivan, Lucia Morbidelli, Roberta Spaccapelo, Cosima Baldari, Stefania Butini, Ettore Novellino, Giuseppe Campiani, Lucia Altucci, Michel Steinmetz, Simone Brogi, Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents, European Journal of Medicinal Chemistry, 2019, p290-320
S. Federico, T. Khan, N. Relitti , G. Chemi, M. Brindisi , S. Brogi, E. Novellino, D.M. Zisterer, G. Campiani, S. Gemma, S. Butini, A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents, Tetrahedron Letters, 2018
O'Boyle, NM, Barrett, I, Greene, LM, Carr, M, Fayne, D, Twamley, B, Knox, AJS, Keely, NO, Zisterer, DM, Meegan, MJ, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ER-alpha and ER-beta Activity, Journal of Medicinal Chemistry, 61, (2), 2018, p514 - 534
Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ, Zisterer DM., Involvement of NF-kB in mediating the anti-tumour effects of combretastatins in T cells., Investigational new drugs, 36, (4), 2018, p523-535
Previtali, V. and Trujillo, C. and Amet, R. and Zisterer, D.M. and Rozas, I., Effect of isouronium/guanidinium substitution on the efficacy of a series of novel anti-cancer agents, MedChemComm, 9, (4), 2018, p735-743
Meegan MJ, Nathwani S, Twamley B, Zisterer DM, O'Boyle NM., Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents., European Journal of Medicinal Chemistry, 125, 2017, p453 - 463
Geoghegan F, Chadderton N, Farrar GJ, Zisterer DM, Porter RK., Direct effects of phenformin on metabolism/bioenergetics and viability of SH-SY5Y neuroblastoma cells., Oncology letters, 14, (5), 2017, p6298-6306
Malebari, AM, Greene, LM, Nathwani, SM, Fayne, D, O'Boyle, NM, Wang, S, Twamley, B, Zisterer, DM, Meegan, MJ, Beta-lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285
Kelly PM, Keely NO, Bright SA, Yassin B, Ana G, Fayne D, Zisterer DM, Meegan MJ., Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation., Molecules (Basel, Switzerland), 22, (9), 2017, p1440-
Malebari, A.M. and Greene, L.M. and Nathwani, S.M. and Fayne, D. and O'Boyle, N.M. and Wang, S. and Twamley, B. and Zisterer, D.M. and Meegan, M.J., β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells, European Journal of Medicinal Chemistry, 130, 2017, p261-285
Kinsella P, Greene LM, Bright SA, Pollock JK, Butini S, Campiani G, Bauer S, Williams DC, Zisterer DM, The novel pyrrolo-1,5-benzoxazepine, PBOX-15, synergistically enhances the apoptotic efficacy of imatinib in gastrointestinal stromal tumours; suggested mechanism of action of PBOX-15., Investigational new drugs, 34, (2), 2016, 159-167
Brindisi M, Maramai S, Brogi S, Fanigliulo E, Butini S, Guarino E, Casagni A, Lamponi S, Bonechi C, Nathwani SM, Finetti F, Ragonese F, Arcidiacono P, Campiglia P, Valenti S, Novellino E, Spaccapelo R, Morbidelli L, Zisterer DM, Williams CD, Donati A, Baldari C, Campiani G, Ulivieri C, Gemma S., Development of novel cyclic peptides as pro-apoptotic agents., European Journal of Medicinal Chemistry, 117, 2016, p301 - 320
Lennon JC, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM, Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells., Investigational new drugs, 34, (5), 2016, p663-76
Greene TF, Wang S, Greene LM, Nathwani SM, Pollock JK, Malebari AM, McCabe T, Twamley B, O'Boyle NM, Zisterer DM, Meegan MJ, Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents., Journal of Medicinal Chemistry, 59, (1), 2016, p90 - 113
Kahvedzic -Seljubac A, Nathwani S.-M, Zisterer D.M, Rozas I, Isouronium and N-hydroxyguanidinium derivatives as Cell growth inhibitors: A comparative study, European Journal of Medicinal Chemistry, 117, 2016, p269 - 282
Kelly PM, Bright SA, Fayne D, Pollock JK, Zisterer DM, Williams DC, Meegan MJ, Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles., Bioorganic & medicinal chemistry, 24, (18), 2016, p4075-99
Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M, Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells., Cancer biology & therapy, 17, (8), 2016, p849 - 858
Greene LM, Nathwani SM, Zisterer DM., Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T-cell acute lymphoblastic leukemia cells via upregulation of death receptor 5., Oncology Letters, 12, (4), 2016, p2900 - 2905
Greene L.M, Butini S, Campiani G, Williams D.C, Zisterer D.M, Pre-clinical evaluation of a novel class of anti-cancer agents, the Pyrrolo-1, 5-benzoxazepines, Journal of Cancer, 7, (15), 2016, p2367 - 2377
Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM, The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL"induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells., International journal of oncology, 49, (1), 2016, p74-88
Carr M, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ., Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells., Journal of Enzyme Inhibition and Medicinal Chemistry, 31, 2016, p117-130
Keely, N.O. and Carr, M. and Yassin, B. and Ana, G. and Lloyd, D.G. and Zisterer, D. and Meegan, M.J., Design, synthesis and biochemical evaluation of novel selective estrogen receptor ligand conjugates incorporating an endoxifen-combretastatin hybrid scaffold, Biomedicines, 4, (3), 2016
Greene LM, Meegan MJ, Zisterer DM, Combretastatins: More Than Just Vascular Targeting Agents?, The Journal of pharmacology and experimental therapeutics, 355, (2), 2015, p212-27
Spallarossa A, Caneva C, Caviglia M, Alfei S, Butini S, Campiani G, Gemma S, Brindisi M, Zisterer DM, Bright SA, Williams CD, Crespan E, Maga G, Sanna G, Delogu I, Collu G, Loddo R, Unconventional Knoevenagel-type indoles: Synthesis and cell-based studies for the identification of pro-apoptotic agents., European journal of medicinal chemistry, 102, 2015, p648-60
O'Callaghan K, Palagano E, Butini S, Campiani G, Williams DC, Zisterer DM, O'Sullivan J, Induction of apoptosis in oral squamous carcinoma cells by pyrrolo-1,5-benzoxazepines., Molecular medicine reports, 12, (3), 2015, p3748-54
Lennon JC, Bright SA, Carroll E, Butini S, Campiani G, O'Meara A, Williams DC, Zisterer DM, The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells., Biochemical pharmacology, 87, (4), 2014, p611-24
Pollock, JK, Verma,NK, O'Boyle, NM, Carr, MG, Meegan, MJ, Zisterer, DM, Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway, Biochemical Pharmacology, 92, (4), 2014, p544-557
O'Boyle, NM, Pollock, JK, Carr, M, Knox, AJS, Nathwani, SM, Wang, S, Caboni, L, Zisterer, DM, Meegan, MJ, Beta-Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand, Journal of Medicinal Chemistry, 57, (22), 2014, p9370 - 9382
O'Boyle NM, Pollock JK, Carr M, Knox AJ, Nathwani SM, Wang S, Caboni L, Zisterer DM, Meegan MJ., β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., Journal of medicinal chemistry, 57, (22), 2014, p9370-9382
Diez-Cecilia, E. Kelly, B. Perez, C. Zisterer, D.M. Nevin, D.K. Lloyd, D.G. Rozas, I., Guanidinium-based derivatives: Searching for new kinase inhibitors, European Journal of Medicinal Chemistry, 81, 2014, p427 - 441
Gangemi, G. and Gazzerro, P. and Fiore, D. and Chiara Proto, M. and Butini, S. and Gemma, S. and Casagni, A. and Laezza, C. and Vitale, M. and Ligresti, A. and Dimarzo, V. and Zisterer, D.M. and Nathwani, S. and Clive Williams, D. and Campiani, G. and Bifulco, M., Erratum: PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines (European Journal of Pharmacology (2013) 714:1-3 (379-387)), European Journal of Pharmacology, 728, (1), 2014, p190
Lysaght, J, Verma, NK, Maginn, EN, Ryan, JM, Campiani, G, Zisterer, DM, Williams, DC, Browne, PV, Lawler, MP, McElligott, AM, The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells, INTERNATIONAL JOURNAL OF ONCOLOGY, 42, (1), 2013, p239-246
Kahvedzic, A, Nathwani, SM, Zisterer, DM, Rozas, I, Aromatic Bis-N-hydroxyguanidinium Derivatives: Synthesis, Biophysical, and Biochemical Evaluations, Journal of Medicinal Chemistry, 56, (2), 2013, p451-459
Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive Williams D, Campiani G, Bifulco M, PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines., European journal of pharmacology, 2013
Nathwani, SM, Hughes, L, Greene, LM, Carr, M, O'Boyle, NM, McDonnell, S, Meegan, MJ, Zisterer, DM, Novel cis-restricted beta-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro, ONCOLOGY REPORTS, 29, (2), 2013, p585-594
Greene LM, Nolan DP, Regan-Komito D, Campiani G, Williams DC, Zisterer DM, Inhibition of late-stage autophagy synergistically enhances pyrrolo-1,5-benzoxazepine-6-induced apoptotic cell death in human colon cancer cells., International journal of oncology, 2013
Greene LM, Wang S, O'Boyle NM, Bright SA, Reid JE, Kelly P, Meegan MJ, Zisterer DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer., Oncology reports, 29, (6), 2013, p2451-8
Greene, LM, Wang, S, O'Boyle, NM, Bright, SA, Reid, JEA, Kelly, PJ, Meegan, MJ, Zisterer, DM, Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer, Oncology Reports, 29, (6), 2013, p2451-2458
O'Boyle, NM, Greene, LM, Keely, NO, Wang, S, Cotter, TS, Zisterer, DM, Meegan, MJ, Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting beta-lactam combretastatins, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 62, 2013, p705-721
Keely, NO, Zisterer, DM, Meegan, MJ, Design, Synthesis and Biochemical Evaluation of Estrogen Receptor Ligand Conjugates as Tumour Targeting Agents, LETTERS IN DRUG DESIGN & DISCOVERY, 9, (3), 2012, p295-304
Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, Biochemical Pharmacology, 84, (5), 2012, p612-624
Greene, LM, O'Boyle, NM, Nolan, DP, Meegan, MJ, Zisterer, DM, The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells, BIOCHEMICAL PHARMACOLOGY, 84, (5), 2012, p612-624
Forde JC, Maginn EN, McNamara G, Martin LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M, Lynch TH, Hollywood D, Marignol L, Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro., Cancer biology & therapy, 11, (4), 2011, p421-8
Bane, F.T., Bannon, J.H., Pennington, S.R., Campiani, G., Williams, D.C., Zisterer, D.M., Mc Gee, M.M., The microtubule-targeting agents, PBOX-6 [Pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and Pin1, in malignant hematopoietic cells (Journal of Pharmacology and Experimental Therapeut (2009) 329, (38-47)), 2011, p729
Butini S., Gemma S., Brindisi M., Borrelli G., Lossani A., Ponte A.M., Torti A., Maga G., Marinelli L., La Pietra V., Fiorini I., Lamponi S., Campiani G., Zisterer D.M., Nathwani S.M., Sartini S., La Motta C., Da Settimo F., Novellino E., Focher F. , Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies. , Journal of Medicinal Chemistry, 54, (5), 2011, p1401 - 1420
O'Boyle, N.M., Knox, A.J.S., Price, T.P., Williams, D.C., Zisterer, D.M., Lloyd, D.G., Meegan, M.J., Lead identification of beta-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90, Bioorganic & Medicinal Chemistry, 19, (20), 2011, p6055-6068
Greene L.M., Carr M., Keeley N.O., Lawler M., Meegan M.J., Zisterer D.M., BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells. , International Journal of Molecular Medicine, 27, (5), 2011, p715 - 723
O'Boyle, NM, Carr, M, Greene, LM, Keely, NO, Knox, AJS, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, Biochemical and Molecular Modelling Studies of Antiproliferative Azetidinones causing Microtubule Disruption and Mitotic Catastrophe, European Journal of Medicinal Chemistry, 46, (9), 2011, p4595 - 4607
Treatment of Chronic Myeloid leukaemia: current practise and future prospects in, editor(s)Steffen Koschmieder and Utz Krug , Myeloid Leukemia Clinical Diagnosis & Treatment, Croatia, Intech, 2011, pp1 - 24, [Daniela M. Zisterer]
O'Boyle, NM, Greene, LM, Bergin, O, Fichet, JB, McCabe, T, Lloyd, DG, Zisterer, DM, Meegan, MJ, Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones, Bioorganic & Medicinal Chemistry, 19, (7), 2011, p2306-2325
Maginn EN, Browne PV, Hayden P, Vandenberghe E, McDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams DC, Zisterer DM, Lawler MP, McElligott AM., PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells., British Journal of Cancer, 104, (2), 2011, p281 - 289
Nathwani,SM, Butler, S, Fayne,D, McGovern,NN, Sarkardi,B, Meegan,MJ, Lloyd,DG, Campiani,G, Lawler,M, Williams,DC, and Zisterer, DM, Novel Microtubule targetting agents, pyrrolo-1,5,benzoxazepines induce apoptosis in multi-drug-resistant cancer cells, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 66, (3), 2010, p585 - 596
S A Bright, A M McElligott, J W O'Connell, L O'Connor, P Carroll, G Campiani, M W Deininger, E Conneally, M Lawler, D C Williams, and D.M Zisterer, Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo , British Journal of Cancer, 102, 2010, p1474 - 1482
Miriam Carr, Lisa M. Greene, Andrew J.S. Knox, David G Lloyd, Daniela M. Zisterer and Mary J. Meegan, Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects, European Journal of Medicinal Chemistry, 45, (12), 2010, p5752-5766
Greene LM, Nathwani SM, Bright SA, Fayne D, Croke A, Gargliardi M, Mc Elligott AM, O'Connor L, Carr M, Keely NO, O'Boyle NM, Carroll P, Sarkadi B, Conneally E, Lloyd DG, Lawler M, Meegan MJ, Zisterer DM, The vascular targeting agent Combretastatin-A4 and a novel cis-restricted {beta}-lactam analogue CA-432 induce apoptosis in human chronic myeloid leukemia cells and in ex vivo patient samples including those displaying multidrug resistance., The Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302 - 313
Greene,. L.M., Nathwani, S.M., Bright, S.A., Fayne, D., Croke, A., Gagliardi,M., McElligott, A.M., O'Connor, L.M., Carr, M.G., Keely, N.O., O'Boyle, N.M., Carroll, P.V., Sarkadi, B., Conneally, E.C., Lloyd,D.G., Lawler, M.P., Meegan, M.J., Zisterer, D.M., The vascular targeting agent combretastatin-A4 and a novel cis-restricted beta-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance, Journal of Pharmacology and Experimental Therapeutics, 335, (2), 2010, p302-313
Sandra A. Bright, Giuseppe Campiani, Michael W. Deininger, Mark Lawler, D. Clive Williams and Daniela M. Zisterer, Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment , Biochemical Pharmacology, 80, 2010, p31 - 38
Barrett, I., Carr, M.G., O'Boyle, N.M., Greene, L.M., Knox, A., Lloyd, D.G., Zisterer, D.M., Meegan, M.J., Lead identification of conformationally restricted benzoxepin type combretastatin analogs: Synthesis, antiproliferative activity, and tubulin effects, Journal of Enzyme Inhibition and Medicinal Chemistry, 25, (2), 2010, p180-194
Nathwani, S-M., Butler, S., Meegan, M.J., Campiani, G., Lawler, M., Williams, D.C. & Zisterer, D.M., Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines., Cancer Chemotherapy and Pharmacology, 65, (2), 2010, p289-300
Seema-Maria Nathwani , Suzanne M. Cloonan, Maeve Stronach, Giuseppe Campiani, Mark Lawler, D. Clive Williams and Daniela M. Zisterer, Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce cell cycle arrest and apoptosis in prostate cancer cells. , Oncology Reports, 24, 2010, p1499 - 1507
Barrett I, Carr M, O'Boyle N, Greene LM, Knox AJ, Lloyd DG, Zisterer DM, Meegan MJ, Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects., Journal of enzyme inhibition and medicinal chemistry, 25, (2), 2010, p180-94
O'Boyle NM, Carr M, Greene LM, Bergin O, Nathwani SM, McCabe T, Lloyd DG, Zisterer DM, Meegan MJ, Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents, Journal of Medicinal Chemistry, 53, (24), 2010, p8569-8584
McElligott, AM, Maginn, EN, Greene, LM, McGuckin, S, Hayat, A, Browne, PV, Butini, S, Campiani, G, Catherwood, MA, Vandenberghe, E, Williams, DC, Zisterer, DM, Lawler, M, The Novel Tubulin-Targeting Agent Pyrrolo-1,5-Benzoxazepine-15 Induces Apoptosis in Poor Prognostic Subgroups of Chronic Lymphocytic Leukemia., Cancer Research, 69, (21), 2009, p8366 - 8375
Daniela Zisterer, Mary Meegan, Niamh O'Boyle, Miriam Carr, Lisa Greene and Thomas Greene, 'Combretastatin Derivatives and Uses Therefor', European Patent Office, EP2338877 A1, 2009
Bright S.A., Greene, L.M., Greene, T.F., Campiani, G., Buitini, S., Brindisi, M., Lawler, M., Meegan, M.J., Williams, D.C. and Zisterer, D.M. , The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells, Biochemical Pharmacology, 77, (3), 2009, p310-321
Bane, F.T., Pennington, S.R., Campiani, G., Williams, D.C., Zisterer, D.M. & Mc Gee, M.M. , The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells., Journal of Pharmacology and Experimental Therapeutics, 329, 2009, p38-47
Meegan, M.J., Carr, M., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G., Beta-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells., Journal of Enzyme Inhibition and Medicinal Chemistry, 23, (5), 2008, p668-685
Verma NK, Dempsey E, Conroy J, Olwell P, Mcelligott AM, Davies AM, Kelleher D, Butini S, Campiani G, Williams DC, Zisterer DM, Lawler M, Volkov Y., A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin., Journal of Molecular Medicine, 86, (4), 2008, p457-469
Barrett, I., Meegan, M.J., Hughes, R.B., Carr, M., Knox, A.J.S. Artemenko, N., Golfis, G., Zisterer, D.M. & Lloyd, D.G., Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators., Bioorganic & Medicinal Chemistry, 16, (21), 2008, p9554-9973
Greene, LM, Campiani, GC, Lawler, M, Williams, DC and Zisterer, DM, BubR1 is Required for a Sustained Mitotic Spindle checkpoint arrest in Human Cancer cells treated with a tubulin-targetting pyrrolo-1,5-benzoxazepine, Molecular Pharmacology, 73, (2), 2008, p419 - 430
Meegan, M.J., Barrett, I., Zimmmermann, J., Knox, A.J.S., Zisterer, D.M. & Lloyd, D.G. , Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells. , Journal of Enzyme Inhibition and Medicinal Chemistry, 22, (5), 2007, p655-66
Smith, H.M., Knox, A.S., Zisterer, D.M., Lloyd, D.G., & Meegan, M.J. , Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives., Medicinal Chemistry, 3, (2), 2007, p135 - 155
Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM., STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells., Journal of Pharmacology and Experimental Therapeutics, 321, (1), 2007, p288-297
Knox AJ, Meegan MJ, Sobolev V, Frost D, Zisterer DM, Williams DC, Lloyd DG., Target specific virtual screening: optimization of an estrogen receptor screening platform., Journal of Medicinal Chemistry, 50, (22), 2007, p5301-5310
Lloyd, D.G., Smith, H.M., O'Sullivan, T., Knox, A.S., Zisterer, D.M. & Meegan, M.J. , Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes : Synthesis, Structure-Activity Relationships and Molecular Modeling Study for Flexible Estrogen Receptor Antagonists , Medicinal Chemistry, 2, (2), 2006, p147 - 168
Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler MP, Williams C, Zisterer DM., Identification of tubulin as the molecular target of pro-apoptotic pyrrolo-1,5-benzoxazepines., Molecular Pharmacology, 70, (1), 2006, p60-70
McGrath, LB, Onnis, V, Campiani, G, Williams, DC, Zisterer, DM and McGee, MM, Caspase-activated DNase (CAD)-independent oligonucleosomal DNA fragmentation in chronic myeloid leukaemia cells; a requirement for serine protease and Mn(2+)-dependent acidic endonuclease activity., Apoptosis, 11, (9), 2006, p1473 - 1487
Lloyd DG, Smith HM, O'Sullivan T, Zisterer DM, Meegan MJ, Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators, Medicinal Chemistry, 1, (4), 2005, p335 - 353
McGee, MM, Gemma, S, Rammunno, A, Zisterer,DM, Fatterusso, C, Catalanotti, B, Butini, S, Fiorini,I, Pisano, C, Cucco, C, Novellino, E, Nacci, V, Williams, DC and Campiani, G, Pyrolo [1,5] benzoxathiazepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target., Journal of Medicinal Chemistry, 48, (13), 2005, p4367 - 4377
Greene, L.M., Fleeton, M., Mulligan, J., Chikana, G., Sheahan, B.J., Atkins, G.J., Campiani, G., Nacci, V., Lawler, M., Williams, D.C. and Zisterer, D.M., The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status, and inhibits breast tumour growth in vivo, Oncology Reports, 14, 2005, p1357 - 1363
Lloyd DG, Hughes RB, Zisterer DM, Williams DC, Fattorusso C, Catalanotti B, Campiani G, Meegan MJ., Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor, Journal of Medicinal Chemistry, 47, (23), 2004, p5612 - 5615
M. M. Mc Gee, L. M. Greene, S. Ledwidge, G. Campiani, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Selective induction of apoptosis by the pyrrolo-1,5-benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine (PBOX-6) in Leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL, The Journal of pharmacology and experimental therapeutics, 310, (3), 2004, p1084-1095
Mulligan J.M., Campiani G., Ramunno A., Nacci V., Zisterer D.M. , Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human astrocytoma cells by pyrrolo-1,5-benzoxazepine, PBOX-21., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1639, (1), 2003, p43 - 52
Quinlan, C.A., O'Sullivan, M.I., Zisterer, D.M. & Tipton, K.F., In vitro cytotoxicity of a composite resin and compomer., International Endodontic Journal, 35, (1), 2002, p47 - 55
M. M. Mc Gee, E. Hyland, G. Campiani, A. Ramunno, V. Nacci and D. M. Zisterer, Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6, FEBS letters, 515, (1-3), 2002, p66-70
M. M. Mc Gee, G. Campiani, A. Ramunno, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells, The Journal of Biological Chemistry, 277, (21), 2002, p18383-18389
Campiani, G., Ramuno, A., Fiorini, I., Nacci, V., Morelli, E., Novellino, E., Menninni, T., Zisterer, D.M., Williams, D.C. , Synthesis of new molecular probes for investigation of steroid biosynthesis induced by selective interaction with peripheral-type benzodiazepine receptors (PBR)., Journal Medicinal Chemistry, 45, (19), 2002, p4276 - 4281
D. M. Zisterer, M. M. McGee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler and D. C. Williams, Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents, Biochemical Society transactions, 29, (6), 2001, p704-706
M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myeloid leukemia (cml) cells by bypassing the apoptotic suppressor bcr-abl, TheScientificWorldJournal [electronic resource], 1, (1 Suppl 3), 2001, p109
M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myeloid leukemia (cml) cells by bypassing the apoptotic suppressor bcr-abl, TheScientificWorldJournal [electronic resource], 1, (1 Suppl 3), 2001, p109
M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl, The Journal of pharmacology and experimental therapeutics, 296, (1), 2001, p31-40
M. M. Mc Gee, G. Campiani, A. Ramunno, C. Fattorusso, V. Nacci, M. Lawler, D. C. Williams and D. M. Zisterer, Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl, The Journal of Pharmacology and Experimental Therapeutics, 296, (1), 2001, p31-40
Meegan, M., Hughes, R., Lloyd, D.G., Zisterer, D.M. & Williams, D.C. , Flexible estrogen receptor modulators: design, synthesis and antagonistic effects in human MCF-7 breast cancer cells. , Journal Medicinal Chemistry, 44, (7), 2001, p1072 - 1084
M. Marangolo, M. M. McGee, K. F. Tipton, D. C. Williams and D. M. Zisterer, Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B, Neurotox Research, 3, (4), 2001, p397-409
Meegan MJ, Hughes RB, Lloyd DG, Williams DC, Zisterer DM, Ethyl side-chain modifications in novel flexible antiestrogens--design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line, Anticancer Drug Design , 16, (1), 2001, p57 - 69
Zisterer, D.M., Campiani., Nacci, V. & Williams, D.C. , Pyrrolobenzoxazepines induce apoptosis in HL-60, Jurkat and Hut-78 cells: A new class of apoptotic agents., Journal Pharmacology and Experimental Therapeutics, 293, (1), 2000, p48 - 59
Zisterer D.M., Campiani, G., Garafalo, A., Nacci, V. and Williams, D.C. , Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: Absence of correlation with binding to the peripheral-type benzodiazepine binding site, Biochemical Pharmacology, 55, (4), 1998, p397 - 403
Zisterer, D.M. and Williams, D.C., Peripheral-type benzodiazepine receptors, General Pharmacology, 29, (3), 1997, p305 - 314
Different specificities for taurine analogues and their target sites in brain. in, editor(s)Teelken and Korf , Neurochemistry, 1997, pp959 - 962, [19. Marangolo, M., Zisterer, D.M., Williams, D.C., Tipton, K.F., Dixon, H.B.F. and Della Corte, L.]
Woods MJ, Zisterer DM, Williams DC. , Two cellular and subcellular locations for the peripheral-type benzodiazepine receptor in rat liver. , Biochemical Pharmacology, 51, (10), 1996, p1283 - 1292
Campiani G, Nacci V, Fiorini I, De Filippis MP, Garofalo A, Ciani SM, Greco G, Novellino E, Williams DC, Zisterer DM, Woods MJ, Mihai C, Manzoni C, Mennini T. , Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands., Journal of Medicinal Chemistry, 39, (18), 1996, p3435 - 3450
D. M. Zisterer, P. N. Moynagh and D. C. Williams, Hexachlorocyclohexanes inhibit steroidogenesis in Y1 cells. Absence of correlation with binding to the peripheral-type benzodiazepine binding site, Biochemical Pharmacology, 51, (10), 1996, p1303-1308
D. M. Zisterer, C. Sunol, P. N. Moynagh, D. C. Williams and E. Rodriguez-Farre, PK 11195 reduces the brain availability of lindane in rats and the convulsions induced by this neurotoxic agent, Life Sciences, 57, (25), 1995, p2359-2364
Zisterer DM, Gorman AM, Williams DC, Murphy MP. , The effects of the peripheral-type benzodiazepine acceptor ligands, Ro5-4864 and PK 11195, on mitochondrial respiration. , Methods and Findings in Experimental and Clinical Pharmacology, 14, (2), 1992, p85 - 90
Non-Peer-Reviewed Publications
Eavan C. McLoughlin, Patricia Hannon Barroeta, Daniela M. Zisterer, and Niamh M. O'Boyle, P41: A comparison of chiral diastereomeric versus kinetic enzymatic resolution for enantioseparation of microtubule depolymerising beta-lactams, 30th Annual GP2A Medicinal Chemistry Conference, Dublin, 24-26 August 2022, 2022
Amet R, Rozas I, McElligott AM, Browne P and Zisterer DM , Novel Anti-Cancer Therapeutics for Multiple Myeloma that target the STAT3 signalling pathway,, Haematology Association of Ireland, Galway, 11th October , 2019
Amet R., Previtali V., Browne P.V., Rozas I., McElligott A.M. & Zisterer D.M. , Novel anti-cancer therapeutics for multiple myeloma which target the STAT3 signalling pathway , European Association for Cancer Research, Amsterdam Netherlands, 1 to 3 february 2018, 2018
Magnano, S., O'Sullivan, J. and Zisterer, D.M., Role of Autophagy in Chemoresistance in Oral Squamous Cell Carcinoma, International Association for Dental Research, London, England, 25 July , 2018
Amet R, Rozas I, McElligott AM, Browne P and Zisterer DM, Novel Anti-Cancer Therapeutics for Multiple Myeloma that target the STAT3 signalling pathway, Irish Association Cancer Research, Crowne Plaza Hotel, Santry, Dublin, 22nd February 2018, 2018
Coyle R, O'Sullivan M. & Zisterer DM, Inhibitor of Apoptosis Proteins as Targets for the Treatment of Malignant Rhabdoid Tumor, Irish Association Cancer Research, Crowne Plaza Hotel, Santry, Dublin, 22nd February 2018, 2018
Coyle R, O'Sullivan M. & Zisterer DM, Inhibitor of Apoptosis Proteins as Targets for the Treatment of Malignant Rhabdoid Tumor, European Association for Cancer Research, Amsterdam Netherlands, 1 to 3 february 2018, 2018
Magnano, S., O'Sullivan, J. and Zisterer, D.M., Pre-clinical evaluation of targeting autophagy for the treatment of Oral Squamous Cell Carcinoma , IADR Irish Divison, Belfast, November 2nd 2017, 2017
Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Microtubule-Destabilising Actions of Piperlongumine and Analogues, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-
Niamh M. O'Boyle, Daniela M. Zisterer, Mary J. Meegan, Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERalpha and ERbeta Activity, Proceedings of the 3rd Int. Electron. Conf. Med. Chem., 3rd International Electronic Conference on Medicinal Chemistry, November 2017, edited by Annie Mayence and Jean Jacques Vanden Eynde , 11, (1), Pharmaceuticals, 2017, pp18-
Research Expertise
Description
There is a continuing requirement for increased understanding of the molecular events underlying the development of cancer. Deregulated apoptosis is a primary cause of tumour development, therefore an increased understanding of this processes will lead to development of novel therapies which target components of this deregulated pathway. In addition, cancer cells are highly adept at surviving under conditions of physiological stress. The autophagy pathway has been identified as a critical cell survival pathway that underpins cellular metabolism. In tumours, deregulation of autophagy frequently occurs contributing to both establishment of neoplastic disease through genomic instability and survival of cancer cells. Autophagy has thus acquired an emerging interest in cancer research offering novel therapeutic targets. Our research programme seeks to understand the molecular mechanisms underlying apoptotic cell death and how deregulated apoptosis leads to cancer. We aim to develop novel therapies which target components of this deregulated pathway. Furthermore, we are interested in determining how tumour resistance to chemotherapy relates to cell survival through autophagic mechanisms. Dr Zisterer has published over one hundred research articles in highly ranked international journals including British Journal of Cancer, Journal of Biological Chemistry and Cancer Research. To date, she has supervised or co-supervised 18 PhD students to completion. She has secured over 3.9 million in research funding from a variety of sources including the European Union, Science Foundation Ireland and the Health Research Board. She is currently project coordinator of an international, inter-sectoral Horizons 2020 Marie Skłodowska-Curie innovative PhD training network entitled Training in Cancer mechanisms and Therapeutics (TRACT), which has secured funding of 2.9 million.Projects
- Title
- Novel Therapeutic Strategies for Malignant Rhabdoid Tumours
- Funding Agency
- TCD
- Date From
- 1/9/2018
- Date To
- 30/8/2022
- Title
- Stat3 signalling as a therapeutic target in Multiple Myeloma
- Funding Agency
- School of Medicine, Trinity College Dublin
- Date From
- 1/9/2016
- Date To
- 30/8/2019
- Title
- Training in Cancer Mechanisms & Therapeutics (TRACT)
- Funding Agency
- EU Horizon 2020
- Date From
- 1/10/2016
- Date To
- 30/9/2020
- Title
- Evaluation of the effect of novel pyrrolobenzoxazepines on primary leukaemia stem cells and on NOTCH signalling in paediatric acute leukaemia cells
- Funding Agency
- Children's Leukaemia Research Project
- Date From
- 1/3/2015
- Date To
- 28/2/2016
- Title
- Inhibitors of apoptosis proteins as targets for treatment of malignant rhabdoid tumours
- Funding Agency
- Trinity College Dublin
- Date From
- 1/9/2015
- Date To
- 30/8/2018
- Title
- Cancer, tubulin and free radicals: new therapy
- Funding Agency
- Irish Research Council
- Date From
- 1/3/2013
- Date To
- 28/2/2015
- Title
- Molecular and Cellular Mechanisms underlying inflammatory processes
- Funding Agency
- PRTLI
- Date From
- 1/9/2012
- Date To
- 31/8/2015
- Title
- Evaluation of the anti-cancer effects of novel pyrrolobenzoxazepines (PBOXs) in gastrointestinal stromal tumours
- Funding Agency
- Health Research Board
- Date From
- January 2012
- Date To
- January 2015
- Title
- Evaluation of TRAIL sensitisation of childhood acute leukaemia cells by novel pyrrolobenzoxazepines
- Funding Agency
- Children's Leukaemia Research Project
- Date From
- October 2011
- Date To
- October 2015
- Title
- Platinum complexes of guanidinium based DNA minor groove binders: conjugating forces towards better anticancer agents
- Funding Agency
- Science Foundation ireland
- Date From
- 2011
- Date To
- 2015
- Title
- Evaluation of the anti-cancer effects of novel pyrrolobenzoxazepines in neuroblastoma
- Funding Agency
- National Children's Hospital Crumlin
- Date From
- October 2010
- Date To
- October 2014
- Title
- Synthesis and biological evaluation of novel combretastatin analogues
- Funding Agency
- Health Research Board
- Date From
- 2009
- Date To
- 2012
- Title
- Rational design of dual targeting anti-cancer agents: novel ligands for hsp90 and tubulin.
- Funding Agency
- Science Foundation Ireland
- Date From
- 2006
- Date To
- 2009
- Title
- 2006Spectroscopic and calorimetric analysis of native and mutant proteins.
- Funding Agency
- Science Foundation Ireland
- Date From
- 2006
- Title
- The use of pyrrolo-1,5-benzoxazepine as powerful probes to dissect components of apoptotic cell death signalling and their development as anti-cancer therapeutics
- Funding Agency
- Science Foundation Ireland
- Date From
- 2005
- Date To
- 2009
- Title
- Evaluation of pyrrolobenzoxazepines as novel anti-angiogenic agents
- Funding Agency
- Enterprise Ireland
- Date From
- 2005
- Date To
- 2006
- Title
- Chemotype switching for identification and mechanistic deconvolution of novel apoptotic agents
- Funding Agency
- Health Research Board
- Date From
- 2004
- Date To
- 2007
- Title
- Development of new diagnostic, prognostic and therapeutic agents in prostate cancer
- Funding Agency
- Irish Cancer Society
- Date From
- 2003
- Date To
- 2006
- Title
- Development of pyrrolo-1,5-benzoxazepine as novel anti-cancer therapeutics
- Funding Agency
- Enterprise Ireland
- Date From
- 2003
- Date To
- 2005
Recognition
Representations
Coordinator of H2020-MSCA-Innovative Training Network entitled TRACT (Training in Cancer Mechanisms & Therapeutics) with budget of 2.9 million.
Coordinator of cancer strand of PRTLI-funded PhD programme 'Molecular and Cellular Mechanisms underlying inflammatory processes in Neuroscience, Infection & Immunity and Cancer'
Member of the Trinity Biomedical Sciences Institute Cancer Drug Discovery Centre
Member, DMMC Cancer Principal Investigators, Trans-institutional grouping of Principal Investigators leading research on Cancer themes
Member, Core Technology PI's, DMMC Principal Investigators leading the development of core technology platforms.
Member, Centre for Molecular Research in Cancer (Proposed), This consortium combines researchers with common interest in understanding cell cycle signaling and regulation with specific focus on two key cancer-related processes (cell cycle control, apoptosis) and/or three specific malignancy types (oesophageal, prostate and haematological).
Member, Prostate Cancer Research Consortium, Multi-centred consortium focused on the development of new diagnostic, prognostic and therapeutic agents for application in prostate cancer.
Awards and Honours
John Scott Fellowship
Provost's PhD Award
Fellowship of Trinity College Dublin
Memberships
Treasurer of the Irish Area Section of the Biochemical Society
Membership of the Irish Association of Cancer Research